公开(公告)号：US20050287137A1

公开(公告)日：2005-12-29

申请号：US11167872

申请日：2005-06-27

Applicant: Patrick Dhaese ,  Pascal Mettens ,  Rene Meykens ,  Philippe Monteyne ,  Torbjorn Schiott ,  Leif Strandberg

Inventor： Patrick Dhaese ,  Pascal Mettens ,  Rene Meykens ,  Philippe Monteyne ,  Torbjorn Schiott ,  Leif Strandberg

IPC: A61K39/395 ,  C07K16/18 ,  C07K16/44

CPC classification number: C07K16/18 ,  C07K2317/622

Abstract: The present invention relates to novel therapies and treatments of atherosclerotic diseases. Accordingly there is provided, methods of treating or preventing atherosclerosis by passive vaccination through administration to a patient of a fully human antibody that is capable of binding to the specific fragments of ApoCIII. Specific human monoclonal antibodies and their use in therapy of atherosclerosis is provided. There is further provided the use of the antibodies of the present invention in medicine.

Abstract translation: 本发明涉及动脉粥样硬化疾病的新疗法和治疗。 因此，提供了通过向能够结合到ApoCIII的特异性片段的完全人抗体的患者施用被动接种来治疗或预防动脉粥样硬化的方法。 提供特异性人单克隆抗体及其在治疗动脉粥样硬化中的应用。 还提供了本发明的抗体在医药中的用途。

公开(公告)号：US5874267A

公开(公告)日：1999-02-23

申请号：US682517

申请日：1996-09-17

Applicant: Rolf Y. Deblaere ,  Jan Desomer ,  Patrick Dhaese

Inventor： Rolf Y. Deblaere ,  Jan Desomer ,  Patrick Dhaese

IPC: C12N15/09 ,  A61K38/00 ,  A61K39/00 ,  C07H21/04 ,  C07K14/235 ,  C07K14/32 ,  C07K14/33 ,  C07K19/00 ,  C12N1/21 ,  C12N15/00 ,  C12N15/12 ,  C12N15/75 ,  C12P21/02 ,  C12R1/07 ,  A61K39/395

CPC classification number: C12N15/75 ,  C07K14/32 ,  A61K38/00 ,  A61K39/00 ,  C07K2319/00

Abstract: A host cell which is provided with a S-layer comprising a fusion polypeptide consisting essentially of:(a) at least sufficient of a S-layer protein for a S-layer composed thereof to assemble, and(b) a heterologous polypeptide which is fused to either the carboxy terminus of (a) or the amino terminus of (a) and which is thereby presented on the outer surface of the said cell; can be used as a vaccine, for screening for proteins and antigens and as a support for immobilizing an enzyme, peptide or antigen. A process of transforming B. Sphaericus cells comprising electroporation is also provided.

Abstract translation: PCT No.PCT / EP95 / 00147 Sec。 371日期1996年9月17日 102（e）日期1996年9月17日PCT提交1995年1月13日PCT公布。 WO95 / 19371 PCT出版物 日期1995年7月20日提供了具有S层的宿主细胞，所述S层包含基本上由以下组成的融合多肽：（a）至少足够的用于组合S层的S层蛋白质组装，以及（b） 融合到（a）的羧基末端或（a）的氨基末端的异源多肽，由此呈现在所述细胞的外表面上; 可用作疫苗，用于筛选蛋白质和抗原，并用作固定酶，肽或抗原的支持物。 还提供了包含电穿孔的B.Sphaericus细胞转化过程。

公开(公告)号：US09574169B2

公开(公告)日：2017-02-21

申请号：US13264395

申请日：2010-04-28

Applicant: Sam Corveleyn ,  Patrick Dhaese ,  Sabine Neirynck ,  Lothar Steidler

Inventor： Sam Corveleyn ,  Patrick Dhaese ,  Sabine Neirynck ,  Lothar Steidler

IPC: C12N1/21 ,  C12N1/04

CPC classification number: A61K35/744 ,  A23K20/10 ,  A23L33/10 ,  A23L33/135 ,  A23V2002/00 ,  A23Y2240/41 ,  A61K47/10 ,  A61K47/12 ,  A61K47/36 ,  C12N1/04 ,  C12N1/20

Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications. More in particular, the invention relates to the increased viability and long-term storage of recombinant bacteria capable of expressing heterologous proteins or peptides and administered to humans or animals for therapeutic or vaccination purposes.

Abstract translation: 本发明包括在不同温度下发现和开发有效的冷冻保护剂组合物，不含脱脂乳或任何其它动物衍生化合物以达到冷冻干燥的乳酸菌（LAB）的长期稳定性，从而保留 冷冻干燥的LAB在储存6个月后的存活率，优选储存9个月后，更优选储存12个月后超过50％。 本发明涉及生产冷冻干燥细菌，特别是乳酸菌的领域。 更具体地，本发明涉及使用冷冻保护剂的新型组合来增加冷冻干燥后细菌的存活力，改善裂解饼的质地以便于研磨，并提高冷冻干燥细菌在不同温度下的长期稳定性 条件。 本发明还涉及用于食品工业或人或动物健康应用的这种冷冻干燥细菌。 更具体地，本发明涉及能够表达异源蛋白质或肽并且施用于人或动物用于治疗或疫苗接种目的的重组细菌的增加的活力和长期储存。

公开(公告)号：US07144717B1

公开(公告)日：2006-12-05

申请号：US09273957

申请日：1999-03-22

Applicant: Huaming Wang ,  Cynthia C. Wang ,  Antoine Amory ,  Patrick Dhaese ,  Annick Lambrechts-Rongvaux

Inventor： Huaming Wang ,  Cynthia C. Wang ,  Antoine Amory ,  Patrick Dhaese ,  Annick Lambrechts-Rongvaux

IPC: C12N9/02 ,  C12N9/04 ,  C12N1/14 ,  C07K1/00

CPC classification number: C11D3/38654 ,  C12N9/0057

Abstract: Disclosed herein are phenol oxidizing enzymes obtainable from species of Stachybotrys which are useful in modifying the color associated with dyes and colored compounds, as well as in anti-dye transfer applications. Also disclosed herein are biologically-pure cultures of strains of the genus Stachybotrys, designated herein Stachybotrys parvispora MUCL 38996 and Stachybotrys charatarum MUCL 38898, which are capable of naturally-producing the novel phenol oxidizing enzymes. Disclosed herein is the amino acid and nucleic acid sequence for Stachybotrys phenol oxidizing enzymes as well as expression vectors and host cells comprising the nucleic acid. Disclosed herein are methods for producing the phenol oxidizing enzyme as well as methods for constructing expression host. Disclosed herein are enzyme compositions comprising phenol oxidizing enzymes obtainable from species of Stachybotrys.

Abstract translation: 本文公开了可从Stachybotrys的物种获得的酚氧化酶，其可用于改变与染料和着色化合物相关的颜色以及抗染料转移应用。 本文还公开了Stachybotrys属（Stachybotrys parvispora MUCL 38996和Stachybotrys charatarum MUCL 38898）的菌株的生物纯培养物，其能够天然产生新的酚氧化酶。 本文公开了Stachybotrys酚氧化酶的氨基酸和核酸序列以及包含该核酸的表达载体和宿主细胞。 本文公开了生产酚氧化酶的方法以及构建表达载体的方法。 本文公开了包含可从Stachybotrys的物种获得的酚氧化酶的酶组合物。

公开(公告)号：US20120039853A1

公开(公告)日：2012-02-16

申请号：US13264395

申请日：2010-04-28

Applicant: Sam Corveleyn ,  Patrick Dhaese ,  Sabine Neirynck ,  Lothar Steidler

Inventor： Sam Corveleyn ,  Patrick Dhaese ,  Sabine Neirynck ,  Lothar Steidler

IPC: A61K35/74 ,  A23L1/30 ,  C12N1/21 ,  C12N1/04 ,  C12N1/20

CPC classification number: A61K35/744 ,  A23K20/10 ,  A23L33/10 ,  A23L33/135 ,  A23V2002/00 ,  A23Y2240/41 ,  A61K47/10 ,  A61K47/12 ,  A61K47/36 ,  C12N1/04 ,  C12N1/20

Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications. More in particular, the invention relates to the increased viability and long-term storage of recombinant bacteria capable of expressing heterologous proteins or peptides and administered to humans or animals for therapeutic or vaccination purposes.

Abstract translation: 本发明包括在不同温度下发现和开发有效的冷冻保护剂组合物，不含脱脂乳或任何其它动物衍生化合物以达到冷冻干燥的乳酸菌（LAB）的长期稳定性，从而保留 冷冻干燥的LAB在储存6个月后的存活率，优选储存9个月后，更优选储存12个月后超过50％。 本发明涉及生产冷冻干燥细菌，特别是乳酸菌的领域。 更具体地，本发明涉及使用冷冻保护剂的新型组合来增加冷冻干燥后细菌的存活力，改善裂解饼的质地以便于研磨，并提高冷冻干燥细菌在不同温度下的长期稳定性 条件。 本发明还涉及用于食品工业或人或动物健康应用的这种冷冻干燥细菌。 更具体地，本发明涉及能够表达异源蛋白质或肽并且施用于人或动物用于治疗或疫苗接种目的的重组细菌的增加的活力和长期储存。

公开(公告)号：US5202237A

公开(公告)日：1993-04-13

申请号：US670498

申请日：1991-03-15

Applicant: Patrick Dhaese

Inventor： Patrick Dhaese

IPC: C12N15/63 ,  C12N15/75

CPC classification number: C12N15/635 ,  C12N15/75 ,  Y10S435/839

Abstract: This invention relates to operator DNA specific for the repressor of .phi.105 and to the use thereof. The sequence of the operator DNA is 5'-GACGGAAATACAAG-3', 5', GTCGGAAATACAAT-3', 5'-GACGAAATTCAAG-3' or 5'-GTCGTGAATACCAT-3.

Abstract translation: 本发明涉及对于phi105的阻遏物特异的操作者DNA及其用途。 操作者DNA的序列是5'-GACGGAAATACAAG-3'，5'，GTCGGAAATACAAT-3'，5'-GACGAAATTCAAG-3'或5'-GTCGTGAATACCAT-3。